Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Cerilliant
Boehringer Ingelheim
Fuji
US Army
Julphar
Chubb
Cantor Fitzgerald
Farmers Insurance

Generated: June 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,050,335

« Back to Dashboard

Which drugs does patent 9,050,335 protect, and when does it expire?

Patent 9,050,335 protects XARTEMIS XR and is included in one NDA.
Summary for Patent: 9,050,335
Title:Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
Abstract: The present disclosure provides extended release pharmaceutical compositions comprising oxycodone and acetaminophen that produce a quick initial onset of analgesia, yet, maintain analgesia for about 12 hours after administration of the composition to a subject in need thereof. The pharmaceutical compositions disclosed herein also reduce the levels of acetaminophen in a subject's blood near the end of the dosing interval because the acetaminophen released by the pharmaceutical composition is being eliminated by a subjects body faster than it is being absorbed.
Inventor(s): Devarakonda; Krishna (St. Louis, MO), Giuliani; Michael J. (Creve Coeur, MO), Gupta; Vishal K. (Hillsborough, NJ), Heasley; Ralph A. (Webster Groves, MO), Shelby; Susan (Creve Coeur, MO)
Assignee: MALLINCKRODT LLC (Hazelwood, MO)
Application Number:13/473,586
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,050,335
Patent Claim Types:
see list of patent claims
Composition; Compound; Dosage form; Formulation; Device;

Drugs Protected by US Patent 9,050,335

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Mallinckrodt Inc XARTEMIS XR acetaminophen; oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 204031-001 Mar 11, 2014 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,050,335

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,858,963 Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia ➤ Try a Free Trial
9,433,582 Gastric retentive extended release pharmaceutical compositions ➤ Try a Free Trial
9,468,636 Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia ➤ Try a Free Trial
8,658,631 Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Merck
Express Scripts
Julphar
Chubb
Fish and Richardson
Federal Trade Commission
Deloitte
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.